Skip navigation
MOST POPULAR RELATED TAGS
  • TOPICS
  • SECTORS
  • COMPANIES

MAD MONEY FEATURES

Podcasts PODCASTS
Watch the Lightning Round whenever and wherever you want.




Widget OFFICIAL MAD MONEY WIDGET
Grab this all-in-one application and get recaps of the show sent right to your desktop or blog.




Soundboard CRAMERS SOUNDBOARD
Admit it: You've always wanted to hit the "They
know nothing!" button. Here’s your chance.




Mad Money PhotosCHECK OUT OUR PHOTOS
Check out Cramer on set, back to school, behind the scenes and more.




ShopSHOP FOR MAD MERCHANDISE
Buy Cramer books, bobbleheads and other Mad Money merchandise.




Ringtones RING TONES
Pick up the phone! It's Cramer! New Mad Money sounds for your cell phone.




Mobile AlertTEXT MESSAGE ALERT
Mad Money's mobile. Get show highlights sent to your phone.







Font size:
May.05
6:22 PM ET
Monday, 5 May 2008
Is Bristol-Myers Breaking Up?

Bristol-Myers Squibb could be on track to break itself up, Cramer said, leaving one of the cheapest pure-play drug companies in the market. Here’s how it could happen:

Bristol-Myers [BMY  Loading...      ()   ] might spin off part of Mead Johnson, BMY’s nutritionals division, bringing in anywhere from about $1 billion to $2 billion in an IPO. We’re not talking about all of Mead, though – maybe 10% or 20% – because the business is such a cash cow that investors aren’t willing to part with it yet (though Cramer said Heinz [HNZ  Loading...      ()   ] could pick up Mead sometime in the future). Add to this IPO money the $4.1 billion BMY got for ConvaTec last Friday, and Bristol-Myers is in good position to buy smaller pharma companies to liven up its pipeline and diversify away from its portfolio risk.

So why the sudden power moves? Because in three years some of Bristol-Myers’ top drugs go off patent, Cramer said. So these steps are being taken to “avert a catastrophic situation,” or at least one that has the potential to hurt BMY’s overall business.

Cramer said tomorrow’s analyst meeting should give some indication of whether or not his theory’s true, so watch for that. But either way he’s confident in BMY’s prospects, whether short term or long. Even if it takes some time for this story to play out, Bristol-Myer’s 5.4% yield is classic Mad Money “pay as you wait” investing. BMY’s almost a win either way.

Questions for Cramer?

Questions, comments, suggestions for the Mad Money website?

© 2008 CNBC, Inc. All Rights Reserved

Permalink: /id/24466911

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis